RecruitingNot ApplicableNCT05953519
Meeting an Unmet Need in Multiple Sclerosis
Meeting an Unmet Need in Multiple Sclerosis (MS): An Evaluation of the Effectiveness of a Transdiagnostic Psychological Treatment and Its Outcomes
Sponsor
Kessler Foundation
Enrollment
24 participants
Start Date
Apr 10, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Diagnosis of multiple sclerosis
- years of age or older
- Experiencing significant depression and/or anxiety
- English-speaking
- Able to provide informed consent
- Access to the internet
Exclusion Criteria6
- History of any other neurological illness (e.g. traumatic brain injury, epilepsy, dementia)
- Current participation in another randomized controlled trial
- Cognitive impairment that would affect my ability to fully participate in the group
- Unable to attend group sessions
- Active participation in another formal clinical group or psychological therapy
- Any other medical or psychological condition that, in the judgement of the investigators, prevents successful participation in the study
Interventions
BEHAVIORALUnified Protocol
The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05953519
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location